Monographie - Cisatracurium besylate

Senaste uppdateringen :
19/11/2024

Cisatracurium besylate

Molekylstruktur

Varunamn

Angivna handelsnamn på läkemedel är enbart vägledande då formulering inklusive hjälpämnen kan variera mellan länder och tillverkare

Bensitrak	Mexiko
Besilato de cisatracurio	Colombia
Cicuryl	Mexiko
Cirium	Colombia
Cis Atracure	Egypten
Cisatracurio	Spanien
Cisatracurium	Belgien, Kanada
Nimbex	Australien, Belgien, Chile, Danmark, Ecuador, Egypten, Finland, Förenade Arabemiraten, Förenta Staterna, Frankrike, Grekland, Iran, Irland, Italien, Kanada, Luxemburg, Malaysia, Nederländerna, Norge, Österrike, Polen, Portugal, Saudi-Arabien, Spanien, Storbritannien, Sverige, Tunisien, Turkiet, Tyskland, Ungern, Venezuela
Nimbium	Colombia

Hänvisningar : Cisatracurium besylate

	Typ	Publikation
59	tidningen	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
299	tidningen	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
533	tidningen	Xu QA, Zhang YP, Trissel LA, Gilbert DL, Martinez JF, Fox JL. Stability of cisatracurium besylate in vials, syringes and infusion admixtures. Am J Health-Syst Pharm 1998 ; 55: 1037-1041.
921	tidningen	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1712	tidningen	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1721	tidningen	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1803	tidningen	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	tidningen	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
2108	tidningen	Trusley C, Kupiec TC, Trissel LA. Compatibility of micafungin injection with other drugs during simulated Y-site co-administration. Int J Pharm Compound 2006 ; 10: 230-232.
2227	tidningen	Trusley C, Ben M, Kupiec TC, Trissel LA. Compatibility and stability of palonosetron hydrochloride with four neuromuscular blocking agents during simulated Y-site administration. Int J Pharm Compound 2008 ; 12, 2: 156-160.
2269	tidningen	Chan P, Bishop A, Kupiec TC, Trissel LA, Gole D, Jimidar IM, Vermeersch H. Compatibility of ceftobiprole medocaril with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2008 ; 65, 16: 1545-1551.
3134	tidningen	Perez Jua En, Maqueda Palau M, Arévalo Rubert Mt, Ribas Nicolau B, Amoros Cerdà SM. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ; 21: 96-103.
3212	tidningen	Ribas Nicolau, B.; P?rez Juan, E.; Amor?s Cerd?, S.M.; Ar?valo Rubert, M.J.; Maqueda Palau, M. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos. Enferm Intensiva 2011 ;22:78-82.
3249	tidningen	Singh BM, Dedhiya MG, Dinunzio J, Chan P, Kupiec TC, Trissel LA, Laudano JB. Compatibility of ceftaroline fosamil for injection with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 2011 ; 68: 2163-2169.
3429	tidningen	Foushee J.A, Fox L.M, Gormley L.R, Lineberger M.S. Physical compatibility of cisatracurium with selected drugs during simulated Y-site administration Am J Health-Syst Pharm 2015 ; 72:483-486
3463	tidningen	Eva Perez Juan, Maria Jos? Arévalo Rubert , Silvia Monica Amoros Cerda , Palau M.M, Nicolau B.R. Fármacos en perfusión continua en la unidad de cuidados intensivos: estudio de compatibilidad. Nursing 2011 ; 29 :62-6
3464	tidningen	Monica Maqueda-Palau, Eva Pérez-Juan, Maria Josep Arévalo-Rubert, Sylvia Monica Amoros-Cerda, Bàrbara Ribas-Nicolau. Compatibilidad física de la amiodarona en perfusión continua Enferm Clin 2011 21:25-29.
3465	tidningen	E. P?rez Juan, M. Maqueda Palau, M. Ar?valo Rubert, B. Ribas Nicolau, S.M. Amor?s Cerd?. Compatibilidad visual y física de la furosemida en mezclas intravenosas para perfusión continua. Enferm Intensiva 2010 ;21:96-103.
3466	tidningen	B. Ribas Nicolau, E. P?rez Juan, S.M. Amor?s Cerd?, M.J. Ar?valo Rubert, M. Maqueda Palau. Compatibilidad física del bicarbonato sódico con fármacos de uso frecuente en la unidad de cuidados intensivos Enferm Intensiva 2011 ;22:78-82.
3540	Laboratorium	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3601	Laboratorium	Cisatracurium Actavis - Résumé des Caractéristiques du Produit Actavis 2012
3823	tidningen	Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R. Compatibilité physique de médicaments administrés dans l’unité de soins intensifs Pharmactuel 2015 ; 48, 3 : 146-152.
3827	affisch	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	affisch	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	affisch	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015
3879	tidningen	Foushee Jaime A, Meredith Pmichaele, Fox Laura M, Grace Edward E. Y-site Physical Compatibility of Beta-blocker Infusions with Intensive Care Unit Admixtures. Int J Pharm Compound 2016 ; 20, 4 : 328-332.
4055	tidningen	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	tidningen	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4358	tidningen	Pignard J, Bourdeaux D, Kauffmann S, Constantin J.M, Sautou V. Stabilité physico-chimique des solutions injectables de bésilate de cisatracurium dans les conditions cliniques d'utilisation Ann Fr Anesth Réanim 2014 ; 33, 5: 304-309.
4433	tidningen	Ghazi I.M, El Nekidy W.S, Sood A, Dulku A, Patel R, Patel K. Y-site Administration of Imipenem/Cilastatin/ Relebactam With Common Intravenous Medications Clin Ther 2020 ; 42, 3: 475-485.
4434	tidningen	Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L. Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-site Administration. Clin Ther 2019 ; 41, 10: 2162-2170.
4465	tidningen	Foushee A, Meredith P, Fox Laura, Wilder A. Y-site physical compatibility of hydrocortisone continuous infusions with admixtures used in critically ill patients. Am J Health-Syst Pharm 2020 ;77,14:1144-1148
4491	tidningen	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pilar P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2020
4507	tidningen	Ross E, Salinas A, Petty K, Her C, Carpenter J. Compatibility of medications with intravenous lipid emulsions: Effects of simulated Y-site mixing. Am J Health-Syst Pharm 2020 ;77,23:1980-1985
4528	tidningen	Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration. Int J Pharm Compound 2021 ;25,1:52-61
4569	tidningen	Lee T.M , Villareal C.L, Meyer L.M. Y-Site Compatibility of Intravenous Levetiracetam With Commonly Used Critical Care Medications. Hosp Pharm 2021 ; 56, 4: 282-286.
4650	Laboratorium	Ceftobiprole (Zevtera 500 mg powder for concentrate for solution for infusion.) Summary of Product Characteristics, Advanz Pharma updated 4 aug 2021. Advanz Pharma 2021
4651	tidningen	De Basagoiti A, Katsumiti A, Abascal S, Bustinza A, López-Giménez L.R, Pascual P, De Miguel M, Campino A. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. Eur J Pedia 2021 ;180,1169–1176.
4769	tidningen	Roche M, Danel C, Simon N, Kouach M, Bouchfaa M, Berneron C, Odou P, Lannoy D. Cisatracurium Besylate 10 mg/mL Solution Compounded in a Hospital Pharmacy to Prevent Drug Shortages : A Stability Study Involving Four Degradation Products. Pharmaceutics 2023 ;15,1404
4801	tidningen	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Mentions Légales